metformin
DrugOther names: Glucophage
NCT Number: NCT01779375
The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Pediatric participants (ages 10-19) will be randomized to one of the following treatment regimens: (1) metformin alone or (2) early intensive treatment with basal insulin glargine followed by metformin.
The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.
Looking for future studies?
Notify Me10 year–19 year
All sexes
Interventional
Phase 3
Childrens Hospital Colorado, Denver, Colorado, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Glucophage
Other names: Insulin glargine, Lantus
Time frame: 3-months after medication washout (Month 15)
Clamp measures of ß-cell response, co-primary outcomes
Time frame: 3-months after a medication washout
Clamp measure of insulin sensitivity
Time frame: 3-months after a medication washout
First phase response
Time frame: End of active intervention (Month 12).
Participants had 12-months of active therapy. Secondary results at the end of active intervention.
Time frame: End of active intervention (Month 12)
Participants had 12-months of active therapy. Secondary results at the end of active intervention.
Time frame: After 12 months of active treatment, and 3 and 9 months of washout
Measures derived the OGTT at the end of the 12 month active intervention period, and following a 3-month and 9-month washout.
RISE Study Group
Network
Restoring Insulin Secretion Pediatric Medication Study
Acronym: RISE Peds
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial DetailsNCT05565534
Breast Cancer, Breast Diseases
Brooklyn, New York, United States
View Trial DetailsNCT05648383
Body Weight, Cardiovascular Diseases
Tirana, Rruga E Dibrës, Albania
View Trial DetailsNCT06912555
Body Weight, Diabetes Mellitus
Zaragoza, Spain
View Trial Details